JP2024518379A - ペプチド－脂質コンジュゲート - Google Patents

ペプチド－脂質コンジュゲート Download PDF

Info

Publication number
JP2024518379A
JP2024518379A JP2023567911A JP2023567911A JP2024518379A JP 2024518379 A JP2024518379 A JP 2024518379A JP 2023567911 A JP2023567911 A JP 2023567911A JP 2023567911 A JP2023567911 A JP 2023567911A JP 2024518379 A JP2024518379 A JP 2024518379A
Authority
JP
Japan
Prior art keywords
peptide
lipid
conjugate
lipid conjugate
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023567911A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024518379A5 (https=
Inventor
ラジャッパン，クマール
タニス，スティーブン
ムクタバーラム，ラジェシュ
サギ，アミット
プラカシュ カルマリ，プリヤ
チブクラ，パドマナブ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arcturus Therapeutics Inc
Original Assignee
Arcturus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arcturus Therapeutics Inc filed Critical Arcturus Therapeutics Inc
Publication of JP2024518379A publication Critical patent/JP2024518379A/ja
Publication of JP2024518379A5 publication Critical patent/JP2024518379A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1275—Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2023567911A 2021-05-05 2022-05-05 ペプチド－脂質コンジュゲート Pending JP2024518379A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163184568P 2021-05-05 2021-05-05
US63/184,568 2021-05-05
PCT/US2022/027857 WO2022235923A2 (en) 2021-05-05 2022-05-05 Peptide-lipid conjugates

Publications (2)

Publication Number Publication Date
JP2024518379A true JP2024518379A (ja) 2024-05-01
JP2024518379A5 JP2024518379A5 (https=) 2025-05-12

Family

ID=83932474

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023567911A Pending JP2024518379A (ja) 2021-05-05 2022-05-05 ペプチド－脂質コンジュゲート

Country Status (7)

Country Link
US (1) US20220378702A1 (https=)
EP (1) EP4333898A4 (https=)
JP (1) JP2024518379A (https=)
CN (1) CN118201639A (https=)
AU (1) AU2022271263A1 (https=)
CA (1) CA3219056A1 (https=)
WO (1) WO2022235923A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119874799A (zh) * 2023-01-18 2025-04-25 仁景(苏州)生物科技有限公司 脂质化合物和脂质纳米颗粒组合物
WO2025166325A1 (en) 2024-02-02 2025-08-07 Editas Medicine, Inc. MODIFIED GUIDE RNAs
WO2025213138A1 (en) 2024-04-05 2025-10-09 Editas Medicine, Inc. Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009158678A1 (en) * 2008-06-27 2009-12-30 Children's Hospital & Research Center At Oakland Lipophilic nucleic acid delivery vehicle and methods of use therefor
JP2011510035A (ja) * 2008-01-25 2011-03-31 ルプレヒト−カールス−ウニベルジタート ハイデルベルク Ｂ型肝炎ウイルス（ＨＢＶ）の疎水性改変ｐｒｅＳ由来ペプチドならびにＨＢＶ侵入インヒビターおよびＨＤＶ侵入インヒビターとしてのそれらの使用
JP2014506574A (ja) * 2011-02-10 2014-03-17 ルプレヒト−カールス−ウニヴェルジテート ハイデルベルク 疎水性修飾ペプチドおよび肝臓特異的標的化のためのその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010530433A (ja) * 2007-06-20 2010-09-09 メルク・シャープ・エンド・ドーム・コーポレイション Ａｐｏａ−１ペプチド模倣体
CN103097413A (zh) * 2010-07-09 2013-05-08 Jv生物公司 脂质缀合抗体
KR102455171B1 (ko) * 2013-12-18 2022-10-14 더 스크립스 리서치 인스티튜트 변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물
WO2019191780A1 (en) * 2018-03-30 2019-10-03 Arcturus Therapeutics, Inc. Lipid particles for nucleic acid delivery
EP3856757A4 (en) * 2018-09-28 2022-06-29 Nutcracker Therapeutics, Inc. Tertiary amino lipidated cationic peptides for nucleic acid delivery
CA3219053A1 (en) * 2021-05-05 2022-11-10 Arcturus Therapeutics, Inc. Lipid compositions comprising peptide-lipid conjugates

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011510035A (ja) * 2008-01-25 2011-03-31 ルプレヒト−カールス−ウニベルジタート ハイデルベルク Ｂ型肝炎ウイルス（ＨＢＶ）の疎水性改変ｐｒｅＳ由来ペプチドならびにＨＢＶ侵入インヒビターおよびＨＤＶ侵入インヒビターとしてのそれらの使用
WO2009158678A1 (en) * 2008-06-27 2009-12-30 Children's Hospital & Research Center At Oakland Lipophilic nucleic acid delivery vehicle and methods of use therefor
JP2014506574A (ja) * 2011-02-10 2014-03-17 ルプレヒト−カールス−ウニヴェルジテート ハイデルベルク 疎水性修飾ペプチドおよび肝臓特異的標的化のためのその使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J VIROL, vol. 84, no. 4, JPN6025053398, 2010, pages 1989 - 2000, ISSN: 0005766041 *
PROC NATL ACAD SCI, vol. 118, no. 9, JPN6025053399, 22 February 2021 (2021-02-22), pages 2025343118, ISSN: 0005766040 *
PROTEIN AND PEPTIDE LETTERS, vol. 9, no. 5, JPN6025053397, 2002, pages 411 - 417, ISSN: 0005766042 *

Also Published As

Publication number Publication date
EP4333898A4 (en) 2026-03-25
CN118201639A (zh) 2024-06-14
EP4333898A2 (en) 2024-03-13
US20220378702A1 (en) 2022-12-01
WO2022235923A3 (en) 2022-12-22
AU2022271263A1 (en) 2023-11-16
CA3219056A1 (en) 2022-11-10
WO2022235923A2 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
US20220370624A1 (en) Lipid compositions comprising peptide-lipid conjugates
US20250049950A1 (en) Nucleic acids and methods of treatment for cystic fibrosis
JP2024518375A (ja) Ｒｎａ送達のためのイオン化可能なカチオン性脂質
US20250213495A1 (en) Method of lyophilizing lipid nanoparticles
US20250136953A1 (en) Compositions and methods for the treatment of ornithine transcarbamylase deficiency
US20230159449A1 (en) Lipid formulations containing nucleic acids and methods of treatment for cystic fibrosis
US20230295081A1 (en) Ionizable cationic lipids for rna delivery
US20220378702A1 (en) Peptide-lipid conjugates
US20240391870A1 (en) Ionizable cationic lipids for rna delivery

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250430

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250430

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260316